| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220224 | Gynecologic Oncology | 2018 | 7 Pages |
Abstract
The PORTEC-4a trial design was proven feasible with a satisfactory patient acceptance rate and an optimized workflow of the determination of the molecular-integrated risk profile. PORTEC-4a is the first randomized trial to investigate use of a molecular-integrated risk profile to determine adjuvant treatment in EC.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
B.G. Wortman, T. Bosse, R.A. Nout, L.C.H.W. Lutgens, E.M. van der Steen-Banasik, H. Westerveld, H. van den Berg, A. Slot, K.A.J. De Winter, K.W. Verhoeven-Adema, V.T.H.B.M. Smit, C.L. Creutzberg, PORTEC Study Group PORTEC Study Group,